



الهيئة المغربية لسوق الرساميل
+d@.E+ +oC4O.oθξ+ | θ%Λo* | ٢٤ΛX.oI
AUTORITÉ MAROCAINE DU MARCHÉ DES CAPITAUX

PRESS RELEASE

AMMC approval of the preliminary prospectus regarding CAPGEMINI SE new shares issuance (capital increase) offered to the company's employees

Rabat, September the 12th 2025

The AMMC (Moroccan Capital Market Authority) informs the public that it has approved, on September the 12th, 2025, the preliminary prospectus regarding CAPGEMINI SE new shares issuance (capital increase) offered exclusively to the company's group employees.

The capital increase will be realized through the issuance of a maximum of 2 700 000 shares.

In Morocco, this offering targets the employees of the companies: CAPGEMINI TECHNOLOGY SERVICES MAROC S.A, ALTRAN MAROC and MG2 ENGINEERING.

For Morocco, the reservation period will run from the 15th of September to the 1st of October, 2025 (included). The subscription price will be set on the 6th of November 2025.

The preliminary prospectus is supplemented by the following :

- Capgemini registration universal document 2024 filed with the AMF on March the 21st, 2025 under the reference D.25.0128;
- The half-year financial report 2025 ;
- The Key information Document in the employee shareholding fund (FCPE) « ESOP CAPGEMINI », compartment « ESOP LEVERAGE P 2025 » filed with the AMF under the reference (C) 990000206029 ;
- The bylaw of shareholding fund (FCPE) « ESOP CAPGEMINI » ;
- The bylaw of the group international shareholding plan (PEGI) ;

The entire preliminary prospectus approved by the AMMC as well as the aforementioned documents are available to the public at the head offices of Capgemini subsidiaries in Morocco listed above, at BMCI and on Capgemini's website. Further, they are accessible on AMMC website: www.ammc.ma

Moroccan Capital Market Authority:

Phone number: 05 37 68 89 71

E-Mail : OperationsFinancieres@ammc.ma

CP/EM/043/2025



www.ammc.ma



[/ammc](https://www.linkedin.com/company/ammc)



[@ammc_news](https://twitter.com/ammc_news)